Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 months after an angioplasty procedure. This meta-analysis of 16 randomized clinical trials and 8,695 patients, the largest analysis of its kind to date, is now posted on the Journal of the American College of Cardiology website and is expected in print later in the year.

"Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents," said Professor Albert Schomig, M.D., from Deutsches Herzzentrum, Technische Universitat in Munich, Germany, one of the authors of the study. "In this meta-analysis of randomized controlled trials, the CYPHER(R) Stent was associated with a significant reduction in the risks of stent thrombosis and reintervention compared to the Taxus Stent. This reinforces the notion that there are marked differences between the CYPHER(R) Stent and the Taxus Stent and that the safety of these drug-eluting stents must be assessed separately."

Professor Schomig added, "We find these data compelling because they are consistent with other documented meta-analyses and reflect data from all of the randomized clinical trials directly comparing these drug-eluting stents. Meta-analyses like this are an important and well-accepted statistical method among clinicians worldwide for documenting similarities and differences between two treatment modalities. We understand and appreciate that such studies are open to various interpretations by researchers and clinicians."

The primary safety endpoint of the meta-analysis was protocol-defined stent thrombosis while the secondary safety endpoints were death and heart attack (myocardial infarction or MI). The primary efficacy endpoint was the need for reintervention (targ
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... FRANCISCO , July 29, 2015  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2015 on Wednesday, August 5, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
(Date:7/29/2015)... 29, 2015 Unilife Corporation (NASDAQ: ... and supplier of injectable drug delivery systems, today ... instant patch pumps for insulin. ... pump that does not require filling or assembly ... pre-assembled like an insulin pen, only three intuitive ...
(Date:7/29/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... second quarter ended June 30, 2015. "We ... and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s President ... cycle management of our products set the stage for ... Financial Highlights , Total net product sales ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14
... 2011 Eli Lilly and Company (NYSE: ... signed agreements with private investors Care Capital and ... and privately-held biotechnology company. BioCritica, based in Central ... development and commercialization of Xigris® (drotrecogin alfa (activated)), ...
... ATLANTA, May 23, 2011 CardioMEMS, Inc ., ... is commercializing a proprietary wireless sensing and communication technology ... and CEO, Jay Yadav, M.D., was presented with a ... by the Atlanta Business Chronicle.  The award was conferred ...
Cached Medicine Technology:Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 2Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 3Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 4Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 5Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 6Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 7CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 2CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 3
(Date:7/30/2015)... Washington, DC (PRWEB) , ... July 30, 2015 ... ... top global managers at multinational organizations and NGO’s, according to a new survey ... today, also shows that property damage and employee medical expenses represented the largest ...
(Date:7/30/2015)... ... , ... HEALTHCAREfirst , the leading provider of cloud-based software, services and ... a free webinar detailing the 2016 proposed rule from CMS for home health. , ... of Regulatory Affairs for the National Association for Home Care and Hospice (NAHC), and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and packaging services for consumer brands, recently completed a consolidation of all of ... Previously, the company operated out of two separate locations situated 11 miles apart. ...
(Date:7/29/2015)... ... 30, 2015 , ... Macro Wealth Management (MWM) Presidents have increased ... Lifetime program by encouraging their clients to donate their MWM planning fees to the ... McClellan and Tim Streid, who see charitable giving as an important part of financial ...
(Date:7/29/2015)... , ... July 29, 2015 , ... According to data ... Medicare Part D premium is expected to remain stable at $32.50, a figure far ... popular Part D program continues to be a bright spot in American health care. ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... K. Bickel, director of the Center for Substance Abuse ... selected as the 2011 recipient of the American Psychological ... Association for Behavior Analysis International, the award recognizes individuals ... to awards chair Cythia Pietras, the award is being ...
... patients participate in clinical trials in part due to a ... published Feb. 11 in The Journal of the National ... trials are accepting participants, according to the National Cancer Institute ... participate in them. Prior studies suggest that most eligible patients ...
... News) -- When someone is trying to fake remorse, ... from one emotion to another very quickly, and speak ... could prove valuable to judges and parole board members, ... and parole release decisions, according to the study authors. ...
... DALLAS Feb. 14, 2011 UT Southwestern ... technology to diagnose Alzheimer,s disease from blood samples ... technology, which uses synthetic molecules to seek out ... eventually in the development of specific biomarkers for ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Feb. 11(HealthDay ... carrying around the raw materials to save at least one ... blood, bone marrow and even the stem cells contained in ... people afflicted with terrible diseases, health officials say. But ...
... disease with a naturally present brain chemical signal ... mechanisms of the disease and open a future ... the University of South Florida Department Neurosurgery and ... Administration Hospital, Tampa. Their findings are published ...
Cached Medicine News:Health News:Brain researcher recognized for contributions to understanding, treatment of drug dependence 2Health News:Few physicians refer patients to cancer clinical trials 2Health News:Few physicians refer patients to cancer clinical trials 3Health News:Clues May Reveal When a Person Is Faking Remorse 2Health News:Preliminary new blood test to detect Alzheimer's disease uncovered 2Health News:Need for Blood and Organ Donors Continues to Grow 2Health News:Need for Blood and Organ Donors Continues to Grow 3Health News:Need for Blood and Organ Donors Continues to Grow 4Health News:Need for Blood and Organ Donors Continues to Grow 5Health News:Naturally occurring brain signaling chemical may be useful in understanding Parkinson's 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
... Difficile Tox A/B II is a second-generation rapid ... A and B in fecal specimens. The test ... results detecting not only the more common toxin ... A-/B+. It's easy to perform, produces no indeterminates ...
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
Medicine Products: